Impact of extremely early antiretroviral therapy to reduce VIral REservoir and induce functional CURE of HIV-1 infection. A pilot comparative study.

Next Previous
Trial Profile

Impact of extremely early antiretroviral therapy to reduce VIral REservoir and induce functional CURE of HIV-1 infection. A pilot comparative study.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Abacavir (Primary) ; Darunavir (Primary) ; Dolutegravir (Primary) ; Emtricitabine (Primary) ; Lamivudine (Primary) ; Maraviroc (Primary) ; Ritonavir (Primary) ; Tenofovir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms VIRECURE

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Nov 2018.
    • 16 Aug 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top